Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 15:47:126706.
doi: 10.1016/j.vaccine.2025.126706. Epub 2025 Jan 8.

Post-exposure prophylaxis for the prevention of measles: A systematic review

Joshua Montroy  1 , Cathy Yan  1 , Faizan Khan  1 , Nicole Forbes  1 , Ramya Krishnan  1 , Matthew Tunis  1 , Marina I Salvadori  2
Affiliations
Free article

Post-exposure prophylaxis for the prevention of measles: A systematic review

Joshua Montroy et al. Vaccine. .
Free article

Abstract

Background: In susceptible individuals, post-exposure prophylaxis (PEP) is often recommended following exposure to measles, however the data that these recommendations are based on are limited. The objective of this systematic review was to evaluate the efficacy/effectiveness and safety of immunoglobulins (Ig) or measles-containing vaccine (MCV) for the prevention of measles.

Methods: Prospective studies evaluating the use of Ig or MCV as PEP in susceptible individuals exposed to measles were eligible for inclusion. For studies evaluating Ig, only studies published since 1970 were eligible. Critical outcomes included confirmed cases of measles infection, and death due to measles. The Cochrane Central Register of Controlled Trials, MEDLINE, Embase, and CINAHL were searched (until May 23, 2024). Risk of bias was assessed using the Cochrane ROBINS-I tool.

Results: Nine studies were included, totalling 660 patients receiving PEP (434 Ig and 226 MCV). Three studies were in children, one in adults, and five included both children and adults. Data were limited in immunocompromised or pregnant individuals. Details regarding intensity of exposure, time from exposure to treatment, and dose of Ig were poorly reported, and all studies presented moderate/serious concerns regarding the risk of bias. Measles infection rates in those who received Ig PEP ranged from 0 to 30 % and from 0 to 15 % in those receiving MCV PEP. Estimates of effectiveness ranged from 76 % (95 % CI 0-94) to 100 % (95 % CI 56.2-99.8 %) for Ig PEP, and from 83.4 % (95 % CI 34.4-95.8) to 100 % (95 % CI not estimable) for MCV PEP.

Discussion: Our systematic review provides a contemporary estimate of measles PEP effectiveness in the context of decreased measles antibody titres in donor-derived blood products over time, and highlights the key limitations to available evidence. Future research should seek to estimate effectiveness of measles PEP in populations of special interest, including immunocompromised and/or pregnant populations.

Keywords: Effectiveness; Immunoglobulin; MMR; Measles; Post-exposure prophylaxis; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Marina I Salvadori reports financial support was provided by PHAC. Marina I Salvadori reports a relationship with Public Health Agency of Canada that includes: employment. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Publication types

LinkOut - more resources